Kirsten Haas1, Jan C Purrucker2, Timolaos Rizos2, Peter U Heuschmann1,3,4, Roland Veltkamp2,5. 1. Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany. 2. Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany. 3. Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany. 4. Clinical Trial Center, University Hospital Würzburg, Würzburg, Germany. 5. Department of Neurology, Alfried Krupp Hospital, Essen, Germany.
Abstract
BACKGROUND: Anticoagulation with vitamin K antagonists and non-vitamin K antagonists oral anticoagulants (NOAC) is effective in stroke prevention in patients with atrial fibrillation. However, anticoagulation also poses a major challenge for emergency treatment of patients suffering ischaemic stroke or intracerebral haemorrhage. AIM: The registry RASUNOA-prime is designed to describe current patterns of emergency management, clinical course and outcome of patients with atrial fibrillation experiencing an acute ischaemic stroke or intracerebral haemorrhage under different anticoagulation schemes prior to stroke (NOAC, vitamin K antagonists or no anticoagulation). METHODS AND DESIGN: RASUNOA-prime (ClinicalTrials.gov, NCT02533960) is a prospective, investigator-initiated, multicentre, observational cohort study aiming to recruit 3000 patients with acute ischaemic stroke and atrial fibrillation, and 1000 patients with acute intracerebral haemorrhage and atrial fibrillation with different anticoagulation schemes pre-stroke. It is a non-interventional triple-armed study aiming at a balanced inclusion of ischaemic stroke and intracerebral haemorrhage patients according to the different anticoagulation schemes. Patients will be followed up for clinical course, management and outcome up to three months after the event. Findings in ischaemic stroke and intracerebral haemorrhage patients on NOAC will be compared with patients taking vitamin K antagonists or no anticoagulant pre-stroke. STUDY OUTCOMES: Primary endpoint for ischaemic stroke patients: occurrence of symptomatic intracerebral haemorrhage, for intracerebral haemorrhage patients: occurrence of secondary haematoma expansion. Secondary endpoints include assessment of coagulation, use of thrombolysis and/or mechanical thrombectomy, occurrence of complications, implementation of secondary prevention. SUMMARY: Describing the current patterns of early management as well as outcome of stroke patients with atrial fibrillation will help guide physicians to develop recommendations for emergency treatment of stroke patients under different anticoagulation schemes.
BACKGROUND: Anticoagulation with vitamin K antagonists and non-vitamin K antagonists oral anticoagulants (NOAC) is effective in stroke prevention in patients with atrial fibrillation. However, anticoagulation also poses a major challenge for emergency treatment of patients suffering ischaemic stroke or intracerebral haemorrhage. AIM: The registry RASUNOA-prime is designed to describe current patterns of emergency management, clinical course and outcome of patients with atrial fibrillation experiencing an acute ischaemic stroke or intracerebral haemorrhage under different anticoagulation schemes prior to stroke (NOAC, vitamin K antagonists or no anticoagulation). METHODS AND DESIGN: RASUNOA-prime (ClinicalTrials.gov, NCT02533960) is a prospective, investigator-initiated, multicentre, observational cohort study aiming to recruit 3000 patients with acute ischaemic stroke and atrial fibrillation, and 1000 patients with acute intracerebral haemorrhage and atrial fibrillation with different anticoagulation schemes pre-stroke. It is a non-interventional triple-armed study aiming at a balanced inclusion of ischaemic stroke and intracerebral haemorrhage patients according to the different anticoagulation schemes. Patients will be followed up for clinical course, management and outcome up to three months after the event. Findings in ischaemic stroke and intracerebral haemorrhage patients on NOAC will be compared with patients taking vitamin K antagonists or no anticoagulant pre-stroke. STUDY OUTCOMES: Primary endpoint for ischaemic stroke patients: occurrence of symptomatic intracerebral haemorrhage, for intracerebral haemorrhage patients: occurrence of secondary haematoma expansion. Secondary endpoints include assessment of coagulation, use of thrombolysis and/or mechanical thrombectomy, occurrence of complications, implementation of secondary prevention. SUMMARY: Describing the current patterns of early management as well as outcome of stroke patients with atrial fibrillation will help guide physicians to develop recommendations for emergency treatment of stroke patients under different anticoagulation schemes.
Entities:
Keywords:
Acute stroke; anticoagulants; intracerebral haemorrhage; non-vitamin K antagonists; vitamin K antagonists
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Timolaos Rizos; Ekkehart Jenetzky; Christian Herweh; Andreas Unterberg; Werner Hacke; Roland Veltkamp Journal: Neurocrit Care Date: 2010-12 Impact factor: 3.210
Authors: Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin Journal: N Engl J Med Date: 2011-08-27 Impact factor: 91.245
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Duncan Wilson; Teddy Y Wu; David J Seiffge; Thomas Meinel; Jan Christoph Purrucker; Johannes Kaesmacher; Urs Fischer Journal: J Neurol Neurosurg Psychiatry Date: 2021-02-04 Impact factor: 10.154
Authors: Serdar Tütüncü; Manuel Olma; Claudia Kunze; Joanna Dietzel; Johannes Schurig; Cornelia Fiessler; Carolin Malsch; Tobias Eberhard Haas; Boris Dimitrijeski; Wolfram Doehner; Georg Hagemann; Frank Hamilton; Martin Honermann; Gerhard Jan Jungehulsing; Andreas Kauert; Hans-Christian Koennecke; Bruno-Marcel Mackert; Darius Nabavi; Christian H Nolte; Joschua Mirko Reis; Ingo Schmehl; Paul Sparenberg; Robert Stingele; Enrico Völzke; Carolin Waldschmidt; Daniel Zeise-Wehry; Peter U Heuschmann; Matthias Endress; Karl Georg Haeusler Journal: J Neurol Date: 2021-10-31 Impact factor: 4.849
Authors: Gerrit M Grosse; Christian Weimar; Nils Kuklik; Anika Hüsing; Andreas Stang; Marcus Brinkmann; Christoph C Eschenfelder; Hans-Christoph Diener Journal: Eur Stroke J Date: 2021-11-17
Authors: Maximilian Schons; Lisa Pilgram; Jens-Peter Reese; Melanie Stecher; Gabriele Anton; Katharina S Appel; Thomas Bahmer; Alexander Bartschke; Carla Bellinghausen; Inga Bernemann; Markus Brechtel; Folke Brinkmann; Clara Brünn; Christine Dhillon; Cornelia Fiessler; Ramsia Geisler; Eckard Hamelmann; Stefan Hansch; Frank Hanses; Sabine Hanß; Susanne Herold; Ralf Heyder; Anna-Lena Hofmann; Sina Marie Hopff; Anna Horn; Carolin Jakob; Steffi Jiru-Hillmann; Thomas Keil; Yascha Khodamoradi; Mirjam Kohls; Monika Kraus; Dagmar Krefting; Sonja Kunze; Florian Kurth; Wolfgang Lieb; Lena Johanna Lippert; Roberto Lorbeer; Bettina Lorenz-Depiereux; Corina Maetzler; Olga Miljukov; Matthias Nauck; Daniel Pape; Valentina Püntmann; Lennart Reinke; Christoph Römmele; Stefanie Rudolph; Julian Sass; Christian Schäfer; Jens Schaller; Mario Schattschneider; Christian Scheer; Margarete Scherer; Sein Schmidt; Julia Schmidt; Kristina Seibel; Dana Stahl; Fridolin Steinbeis; Stefan Störk; Maike Tauchert; Johannes Josef Tebbe; Charlotte Thibeault; Nicole Toepfner; Kathrin Ungethüm; Istvan Vadasz; Heike Valentin; Silke Wiedmann; Thomas Zoller; Eike Nagel; Michael Krawczak; Christof von Kalle; Thomas Illig; Stefan Schreiber; Martin Witzenrath; Peter Heuschmann; Jörg Janne Vehreschild Journal: Eur J Epidemiol Date: 2022-07-29 Impact factor: 12.434